Jasper Therapeutics, Inc. (JSPRW) — 8-K Filings

8-K Filings (16)

• 8-K Filing — Dec 2, 2025
• Jasper Therapeutics Enters Material Definitive Agreement — Sep 19, 2025 Risk: medium
  On September 18, 2025, Jasper Therapeutics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statem
• Jasper Therapeutics Reports Key Corporate Events — Jul 9, 2025 Risk: medium
  Jasper Therapeutics, Inc. filed an 8-K on July 9, 2025, reporting on several key events as of July 8, 2025. These include cost associated with exit or disposal
• Jasper Therapeutics Files 8-K — Jul 7, 2025 Risk: low
  Jasper Therapeutics, Inc. filed an 8-K on July 7, 2025, reporting on other events and financial statements. The company, formerly known as Amplitude Healthcare
• Jasper Therapeutics Files 8-K on Security Holder Vote Matters — Jul 3, 2025 Risk: low
  Jasper Therapeutics, Inc. filed an 8-K on July 3, 2025, to report on the submission of matters to a vote of its security holders. The filing details the company
• Jasper Therapeutics Files 8-K — Jun 16, 2025 Risk: low
  On June 14, 2025, Jasper Therapeutics, Inc. filed an 8-K report detailing other events and financial statements. The company, formerly known as Amplitude Health
• Jasper Therapeutics Terminates Material Agreement — Mar 19, 2025 Risk: medium
  Jasper Therapeutics, Inc. announced on March 14, 2025, the termination of a material definitive agreement. The company, formerly known as Amplitude Healthcare A
• Jasper Therapeutics Files 8-K on Financials — Feb 27, 2025 Risk: low
  Jasper Therapeutics, Inc. filed an 8-K on February 27, 2025, reporting on its results of operations and financial condition, as well as financial statements and
• Jasper Therapeutics Files 8-K — Jan 8, 2025 Risk: low
  Jasper Therapeutics, Inc. filed an 8-K on January 8, 2025, reporting on other events and financial statements. The company, formerly known as Amplitude Healthca
• Jasper Therapeutics Files 8-K on Warrant and Stock Details — Oct 15, 2024 Risk: low
  Jasper Therapeutics, Inc. filed an 8-K on October 15, 2024, reporting an event that occurred on October 14, 2024. The filing indicates changes related to its co
• Jasper Therapeutics Appoints New CMO, Director — Jun 20, 2024 Risk: medium
  Jasper Therapeutics, Inc. announced on June 17, 2024, the appointment of Dr. Jonathan Leipsic as Chief Medical Officer and the election of Ms. Sarah K. Johnson
• Jasper Therapeutics Holds Annual Meeting, Approves Share Increase — Jun 12, 2024 Risk: low
  Jasper Therapeutics, Inc. announced on June 6, 2024, that it held its Annual Meeting of Stockholders. During the meeting, stockholders elected two Class II dire
• Jasper Therapeutics Files 8-K on Financials — Mar 4, 2024 Risk: low
  Jasper Therapeutics, Inc. filed an 8-K on March 4, 2024, reporting on its results of operations and financial condition. The filing also includes financial stat
• Jasper Therapeutics Files 8-K for Material Agreement, Lacks Details — Feb 6, 2024
  Jasper Therapeutics, Inc. filed an 8-K on February 6, 2024, to report an 'Entry into a Material Definitive Agreement' and 'Other Events.' While the filing indic
• Jasper Therapeutics Amends Bylaws, Modifies Security Holder Rights — Jan 4, 2024
  Jasper Therapeutics, Inc. filed an 8-K on January 3, 2024, to report a material modification to the rights of its security holders and amendments to its Article
• Jasper Therapeutics Files Routine 8-K on Jan 2, 2024 — Jan 2, 2024
  Jasper Therapeutics, Inc. filed an 8-K on January 2, 2024, to report a routine event, specifically a Regulation FD Disclosure and Financial Statements and Exhib

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX